Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Oncopeptides AB (publ)    ONCO   SE0009414576

ONCOPEPTIDES AB (PUBL)

(ONCO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Stockholm
01/22/2020 01/23/2020 01/24/2020 01/27/2020 01/28/2020 Date
138.8(c) 134.9(c) 129.2(c) 127.8(c) 133.8 Last
289 745 224 396 440 295 273 431 401 607 Volume
+3.97% -2.81% -4.23% -1.08% +4.69% Change
More quotes
Financials (SEK)
Sales 2019 -
EBIT 2019 -685 M
Net income 2019 -684 M
Finance 2019 912 M
Yield 2019 -
Sales 2020 144 M
EBIT 2020 -658 M
Net income 2020 -648 M
Finance 2020 802 M
Yield 2020 -
P/E ratio 2019 -9,87x
P/E ratio 2020 -11,4x
EV / Sales2019 -
EV / Sales2020 43,7x
Capitalization 7 082 M
More Financials
Company
Oncopeptides AB is a Sweden-based clinical development pharmaceutical company, which is primarily engaged in the healthcare industry. The Company focuses on research and development of cancer treatment solutions. The Company's product Ygalo is a peptidase potentiated alkylator, a type of cytotoxic... 
Sector
Biotechnology & Medical Research
Calendar
01/27 | 05:00amSpecial Situation
More about the company
Surperformance© ratings of Oncopeptides AB (publ)
Trading Rating : Investor Rating : -
More Ratings
Latest news on ONCOPEPTIDES AB (PUBL)
01/27ONCOPEPTIDES PUBL : will host a webcast on Monday, January 27th at 11.00
AQ
01/24ONCOPEPTIDES PUBL : will host a webcast on Monday, January 27 at 11.00 (CET)
AQ
01/07ONCOPEPTIDES PUBL : strengthens its regulatory function by appointing Karin Eklu..
AQ
2019ONCOPEPTIDES PUBL : Bulletin from the Extraordinary General Meeting in Oncopepti..
AQ
2019ONCOPEPTIDES PUBL : Bulletin from the Extraordinary General Meeting in Oncopepti..
AQ
2019ONCOPEPTIDES WILL HOST A WEBCAST ON : 00 to provide an update regarding data pr..
AQ
2019ONCOPEPTIDES PUBL : presents promising data from the Phase 2 ANCHOR combination ..
AQ
2019ONCOPEPTIDES PUBL : presents updated efficacy and safety data from pivotal Phase..
AQ
2019ONCOPEPTIDES WILL HOST A WEBCAST ON : 00 (CET) to provide an update regarding d..
AQ
2019ONCOPEPTIDES PUBL : appoints Joseph Horvat as President North America
AQ
2019ONCOPEPTIDES PUBL : Interim report q3 2019
AQ
2019ONCOPEPTIDES PUBL : Extraordinary General Meeting in Oncopeptides AB
AQ
2019ONCOPEPTIDES PUBL : Extraordinary General Meeting in Oncopeptides AB (publ)
AQ
2019ONCOPEPTIDES PUBL : to Highlight Data from Melflufen Clinical Program in Multipl..
AQ
2019ONCOPEPTIDES AB : - Number of shares and votes in Oncopeptides
AQ
More news
News in other languages on ONCOPEPTIDES AB (PUBL)
01/09BIOTECH TIME : Innate, DBV, AB Science, Valneva, Mauna Kea, Erytech...
2019AVIS D'ANALYSTES DU JOUR : Orange, Ipsen, Altice, Iliad, Rexel, Nexans, LafargeH..
2019STOCK MARKET PARIS : J-15 avant la trêve des confiseurs
2019AVIS D'ANALYSTES DU JOUR : Safran, Sanofi, Tarkett, TechnipFMC, Dassault Système..
2019STOCK MARKET PARIS : Tout est sous contrôle ?
More news
Analyst Recommendations on ONCOPEPTIDES AB (PUBL)
More recommendations
Sector news : Bio Therapeutic Drugs
06:16aREGENERON PHARMACEUTICALS : Sanofi Get FDA Priority Review of Dupixent in Childr..
DJ
02:48aNewmont Acts to Block Rival Barrick -- WSJ
DJ
01/27U.S. Drugmakers Ship Therapies to China, Seeking to Treat Coronavirus
DJ
01/27ELI LILLY AND : Lilly, Incyte Say Baricitinib Meets Primary Endpoint in Phase 3 ..
DJ
01/27America's Gold Giant Bets on Dividends, Improved Mines to Hold Off Rival
DJ
More sector news : Bio Therapeutic Drugs
Chart ONCOPEPTIDES AB (PUBL)
Duration : Period :
Oncopeptides AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ONCOPEPTIDES AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 220,00  SEK
Last Close Price 133,80  SEK
Spread / Highest target 79,4%
Spread / Average Target 64,4%
Spread / Lowest Target 49,5%
EPS Revisions
Managers
NameTitle
Stig Anders Jakob Lindberg Chief Executive Officer
Per Wold-Olsen Chairman
Anders Martin-Löf Chief Financial Officer
Christian Jacques Chief Scientific Officer & Executive VP
Fredrik Lehmann Head-Research, Chemistry, Manufacturing & Control
Sector and Competitors
1st jan.Capitalization (M$)
ONCOPEPTIDES AB (PUBL)1.81%736
GILEAD SCIENCES-1.77%80 754
VERTEX PHARMACEUTICALS3.85%58 468
REGENERON PHARMACEUTICALS-8.04%37 106
WUXI APPTEC CO., LTD.3.98%22 682
GENMAB3.58%14 438